Wednesday, December 2, 2015

ORIC Pharmaceuticals Gets $53M For Cancer Drugs

South San Francisco-based ORIC Pharmaceuticals said today that it has raised $53M in a Series B funding. The company, which is developing small molecule drugs to treat cancer, said the funds came from The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners. The funds go towards initial clinical trials. ORIC Pharmaceuticals' is currently led by interim CEO Richard Heyman.